Here's why Goldman Sachs upgraded IDP Education shares to 'buy'  

Goldman Sachs has recommended growth company IDP Education as a Buy with a target price of $25.40.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDP Education Limited (ASX: IEL) share price was top performer on the S&P/ASX 200 (INDEXASX: XJO) last week, climbing a whopping 36.4% and reaching a record high. IDP Education shares have retreated in morning trade and are currently trading 4.04% lower at $22.55.

IDP Education provides international student placement services and English language testing services. It also runs a string of English language schools in South East Asia and organises educational events and conferences globally. 

The recommendation change

IDP's share price fell 18% between 20 January and 3 February on fears of the impact of the coronavirus. It later surged by 28% in one day on 12 February after an earnings report showing increases against previous calendar period (pcp) of 49% in earnings before interest and tax. 

The company's earnings performance was due to improvements in revenue generation across all business lines and improvements in margin. IDP's core business of student placement saw a 30% volume growth principally from the UK and Canada.

Key to its profitability and revenue growth has been the company's rapid roll out of its computer-delivered International English Language Testing System (IELTS) over 47 countries. In addition, 37 venues were opened during FY20 H1.

Goldman Sachs' recommendation upgrade is based largely on a judgement that the current coronavirus crisis will not pose a "structural" impact on IDP's performance. The company has proven that it can manage the impact of coronavirus thus far, due to the geographical diversity of its operating locations. 

Goldman Sachs estimates that IDP's exposure to China is approximately 10.9% of revenue on a full-year FY20 basis. This is revenue the company is already replacing via revenue streams and in other markets. 

The value proposition

IDP is one of the true recent growth stories of the ASX. Over the past 4 years, it has a compound annual growth rate (CAGR) of 14.2% in sales, 13.7% in earnings per share and 14.8% in cash flow. 

With a share price (CAGR) of 52.4%, $10,000 invested in IDP Education on 1 January 2016 would have been worth $53,909 on 1 January 2020.

IDP has demonstrated a very strong capability for turning capital into increased revenues with a return on capital expended (ROCE) of 63% in FY19 and 75% in FY18.

The company's business model means that expended capital results in additional teachers, marketing and sales resources, and resources to deliver training and student placements, which are all revenue generating units in some form or other. IDP also owns one-third of IELTS, providing an additional revenue stream.

The one issue with the IDP stock is the share price. It is presently trading at a price-to-earnings (P/E) ratio of 71.5. Historically, its P/E ratio has always been high with the FY19 average sitting at 46. The market and Goldman Sachs have clearly factored in future growth potential and expect the company to have a long runway ahead of it.  

Foolish takeaway

Goldman Sachs' change in recommendation was anchored to the growth revealed by IDP in the company's H1 earnings report, which also highlighted that the impact of the coronavirus outbreak has been negligible thus far. 

IDP is a very well managed growth prospect. The size of its market and the company's management have turned it into a capital compounding machine, underscored by its very strong ROCE performance. It is likely to see a full-year FY20 impact from the coronavirus, but at this stage this will be a short-term effect.

At an earnings multiple of approximately 77, investors will need to ask whether they agree this company is well positioned to continue its growth trajectory for years to come.

Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another strong showing from the share market today.

Read more »

Three miners looking at a tablet.
Resources Shares

Own ASX mining shares? Experts say an upswing in commodity prices has begun

HSBC economists Paul Bloxham and Jamie Culling explain why global commodity prices are rising.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Brambles, Lifestyle Communities, Northern Star, and Select Harvests shares are sinking

These shares are having a tough session. But why?

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
Share Market News

Will the Reserve Bank wait for the US Fed to cut interest rates first?

Here's when AMP thinks interest rates will be cut in the US, Australia, New Zealand, Canada and the Eurozone.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Healthco Healthcare, Medadvisor, Ramsay Health Care, and Tamboran shares are rising

These shares are having a strong session. But why?

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Share Gainers

If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

Mesoblast shares have been on a tear this past month. But why?

Read more »

Gold bars on top of gold coins.
Gold

Is it too late to buy gold as an investment in 2024?

Can we still take advantage of gold at new record highs?

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Mergers & Acquisitions

Wesfarmers shares baulk on fresh acquisition gossip

A healthcare company gone nowhere in a decade might be on Wesfarmers' radar.

Read more »